NCT02165917

Brief Summary

Endometriosis is a common disease of women in the reproductive age and is an important cause for female infertility. Endometriosis is often associated with the development of adhesions which further compromises the fertility of the affected women. The main purpose of this study is to investigate the pregnancy rate one year after excision of endometriosis and application of GnRH-analogues (Gonadotropin-releasing hormone) for 3 month. Half of the patients will receive traditional endometriosis treatment with the excision of the endometriotic lesions only. The other half will additionally receive a gel which can reduce adhesion formation (Hyalobarrier®). Further study objective is the investigation in the development of different types of endometriosis-associated pain over a period of one year. Potential study participants are women with endometriosis-associated pain and with a desire to have children. It will be investigated in the study if the use of Hyalobarrier® will result in a higher pregnancy rate due to reduced adhesion development.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started May 2015

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 15, 2014

Completed
2 months until next milestone

First Posted

Study publicly available on registry

June 18, 2014

Completed
11 months until next milestone

Study Start

First participant enrolled

May 1, 2015

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2017

Completed
Last Updated

November 3, 2015

Status Verified

November 1, 2015

Enrollment Period

2 years

First QC Date

April 15, 2014

Last Update Submit

November 2, 2015

Conditions

Keywords

EndometriosisAdhesionsHyalobarrier®Hyaluronic acidAntiadhesion agentAdhesionbarrierPregnancy rate

Outcome Measures

Primary Outcomes (1)

  • Pregnancy rate

    One year after completion of endometriosis treatment (excision followed by 3 month of GnRH-analogues)

Secondary Outcomes (2)

  • Endometriosis-associated pain

    The day before laparoscopy is performed

  • Endometriosis-associated pain

    One year after completion of endometriosis treatment

Study Arms (2)

Excision only

PLACEBO COMPARATOR

Laparoscopic excision of endometriotic lesions followed by 3 month of GnRH-Analogue administration

Procedure: Excision only

Excision plus hyaluronic acid gel

ACTIVE COMPARATOR

Standard Laparoscopic excision of endometriotic lesions plus application of 10 cc of a hyaluronic acid gel (Hyalobarrier® ), followed by 3 month of GnRH-analogue administration

Procedure: Excision plus hyaluronic acid gel

Interventions

Excision of endometriosis foci by laparoscopic standard methods followed by an application of 10 cc Hyaluronic acid gel, in order to prevent postsurgical adhesions.

Excision plus hyaluronic acid gel
Excision onlyPROCEDURE

Excision of endometriosis foci by laparoscopic standard methods only.

Excision only

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Participants are in good general health except for endometriosis related problems;
  • Except for endometriosis, no existence of an obvious diseases which could cause chronic pain or which could cause abdominal pain;
  • The participant must have a desire to have children;
  • Participants must be able to give their consent and must understand the risks associated with a participation in the study;
  • There must be a signed and dated informed consent which was accepted by the local ethic committee

You may not qualify if:

  • Existent pregnancy including ectopic pregnancy;
  • Identification of other causes for the discomfort;
  • Chronic diseases, except endometriosis, which require continuous pain therapy;
  • Previous application of GnRH analogues 6 month prior to study;
  • Concurrent use of systemic corticosteroids, antineoplastic agents and/or radiation;
  • Planned additional general surgical procedures during the operation for removal of the endometriotic lesions;
  • Absence of endometriosis at laparoscopy;
  • Partial resection of the bowel or urinary bladder for removal of endometriosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pius-Hospital, Department of Gynecology, Obstetrics and Gynecological Oncology, Carl von Ossietzky University

Oldenburg, Lower Saxony, 26121, Germany

RECRUITING

MeSH Terms

Conditions

EndometriosisTissue Adhesions

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesCicatrixFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Rudy L De Wilde, Professor

    Pius-Hospital Oldenburg, Department of Gynecology, Obstetrics and Gynecological Oncology

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Rudy L De Wilde, Professor

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor Dr. Dr. med.

Study Record Dates

First Submitted

April 15, 2014

First Posted

June 18, 2014

Study Start

May 1, 2015

Primary Completion

May 1, 2017

Study Completion

May 1, 2017

Last Updated

November 3, 2015

Record last verified: 2015-11

Locations